• About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • CD30 CAR-T Cell Therapy
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • Manufacturing
  • Pipeline
    • TT11 CD30 CAR Ts
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

What are you looking for?

Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
  • About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • CD30 CAR-T Cell Therapy
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • Manufacturing
  • Pipeline
    • TT11 CD30 CAR Ts
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

    tessathe

  • All
  • Career Opportunities
  • home-featured
  • news-pressrelease
  • news-videos
  • Singapore-Product Development
  • US – Human Resource
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory

    Tessa Therapeutics today announced a collaboration agreement with the Agency for Science Technology and Research’s…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

    Tessa Therapeutics today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured in Podium Presentation at the ASGCT 24th Annual Meeting

    Tessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

    Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial…

    Continue Reading
    • Singapore - Finance

    Manager, Finance and Compliance

    Excerpt Publication 2 Sample Excerpt

    Continue Reading
    • Singapore - Clinical Operations and Data Management

    Associate Manager, Clinical Projects

    Excerpt Publication 2 Sample Excerpt

    Continue Reading
    • Singapore - Quality

    Manager/Lead, Quality Control (Bioanalytical)

    Excerpt Publication 2 Sample Excerpt

    Continue Reading
    • Singapore - Manufacturing

    Biotechnologist Lead

    Excerpt Publication 2 Sample Excerpt

    Continue Reading
    • US - Human Resource

    Associate Director/Director, Human Resource (New Jersey)

    Excerpt Publication 2 Sample Excerpt

    Continue Reading
    • US - Clinical Operations

    Senior Manager, Clinical Documentation (New Jersey)

    Excerpt Publication 2 Sample Excerpt

    Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • →
  • ABOUT US
  • TECHNOLOGY
  • PIPELINE
  • PRESS RELEASES & EVENTS
  • CAREERS
  • CONTACT US

SITEMAP          PRIVACY POLICY

© 2021 Tessa Therapeutics Ltd. All rights reserved.